Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

Shi, L; Westwood, S; Baird, AL; Winchester, L; Dobricic, V; Kilpert, F; Hong, SJ; Franke, A; Hye, A; Ashton, NJ; Morgan, AR; Bos, I; Vos, SJB; Buckley, NJ; ten Kate, M; Scheltens, P; Vandenberghe, R; Gabel, S; Meersmans, K; Engelborghs, S; De Roeck, EE; Sleegers, K; Frisoni, GB; Blin, O; Richardson, JC; Bordet, R; Molinuevo, JL; Rami, L; Wallin, A; Kettunen, P; Tsolaki, M; Verhey, F; Lleo, A; Alcolea, D; Popp, J; Peyratout, G; Martinez-Lage, P; Tainta, M; Johannsen, P; Teunissen, CE; Freund-Levi, Y; Frolich, L; Legido-Quigley, C; Barkhof, F; Blennow, K; Zetterberg, H; Baker, S; Morgan, BP; Streffer, J; Visser, PJ; Bertram, L; Lovestone, S; Nevado-Holgado, AJ

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

Introduction: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased towa...

Full description

Bibliographic Details
Authors:	Shi, L, Westwood, S, Baird, AL, Winchester, L, Dobricic, V, Kilpert, F, Hong, SJ, Franke, A, Hye, A, Ashton, NJ, Morgan, AR, Bos, I, Vos, SJB, Buckley, NJ, ten Kate, M, Scheltens, P, Vandenberghe, R, Gabel, S, Meersmans, K, Engelborghs, S, De Roeck, EE, Sleegers, K, Frisoni, GB, Blin, O, Richardson, JC, Bordet, R, Molinuevo, JL, Rami, L, Wallin, A, Kettunen, P, Tsolaki, M, Verhey, F, Lleo, A, Alcolea, D, Popp, J, Peyratout, G, Martinez-Lage, P, Tainta, M, Johannsen, P, Teunissen, CE, Freund-Levi, Y, Frolich, L, Legido-Quigley, C, Barkhof, F, Blennow, K, Zetterberg, H, Baker, S, Morgan, BP, Streffer, J, Visser, PJ, Bertram, L, Lovestone, S, Nevado-Holgado, AJ
Format:	article
Status:	Published version
Publication Date:	2019
Country:	España
Institution:	Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repository:	r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:	oai:iibsantpau.fundanetsuite.com:p2359
Online Access:	https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2359
Access Level:	Open access
Keyword:	Amyloid beta SOMAscan assay Plasma proteomics Replication Causal relationship Tau

id	ES_4f179fd58aed5cfd7821c3e032f337e7
oai_identifier_str	oai:iibsantpau.fundanetsuite.com:p2359
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assayShi, LWestwood, SBaird, ALWinchester, LDobricic, VKilpert, FHong, SJFranke, AHye, AAshton, NJMorgan, ARBos, IVos, SJBBuckley, NJten Kate, MScheltens, PVandenberghe, RGabel, SMeersmans, KEngelborghs, SDe Roeck, EESleegers, KFrisoni, GBBlin, ORichardson, JCBordet, RMolinuevo, JLRami, LWallin, AKettunen, PTsolaki, MVerhey, FLleo, AAlcolea, DPopp, JPeyratout, GMartinez-Lage, PTainta, MJohannsen, PTeunissen, CEFreund-Levi, YFrolich, LLegido-Quigley, CBarkhof, FBlennow, KZetterberg, HBaker, SMorgan, BPStreffer, JVisser, PJBertram, LLovestone, SNevado-Holgado, AJAmyloid betaSOMAscan assayPlasma proteomicsReplicationCausal relationshipTauIntroduction: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. Methods: 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid. Results: A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) e4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. Discussion: The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition. (C) 2019 The Authors. Published by Elsevier Inc.WILEY2019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2359ALZHEIMERS & DEMENTIAISSN: 15525260ISSNe: 15525279reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p23592026-06-14T12:41:47Z
dc.title.none.fl_str_mv	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
title	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
spellingShingle	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay Shi, L Amyloid beta SOMAscan assay Plasma proteomics Replication Causal relationship Tau
title_short	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
title_full	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
title_fullStr	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
title_full_unstemmed	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
title_sort	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
dc.creator.none.fl_str_mv	Shi, L Westwood, S Baird, AL Winchester, L Dobricic, V Kilpert, F Hong, SJ Franke, A Hye, A Ashton, NJ Morgan, AR Bos, I Vos, SJB Buckley, NJ ten Kate, M Scheltens, P Vandenberghe, R Gabel, S Meersmans, K Engelborghs, S De Roeck, EE Sleegers, K Frisoni, GB Blin, O Richardson, JC Bordet, R Molinuevo, JL Rami, L Wallin, A Kettunen, P Tsolaki, M Verhey, F Lleo, A Alcolea, D Popp, J Peyratout, G Martinez-Lage, P Tainta, M Johannsen, P Teunissen, CE Freund-Levi, Y Frolich, L Legido-Quigley, C Barkhof, F Blennow, K Zetterberg, H Baker, S Morgan, BP Streffer, J Visser, PJ Bertram, L Lovestone, S Nevado-Holgado, AJ
author	Shi, L
author_facet	Shi, L Westwood, S Baird, AL Winchester, L Dobricic, V Kilpert, F Hong, SJ Franke, A Hye, A Ashton, NJ Morgan, AR Bos, I Vos, SJB Buckley, NJ ten Kate, M Scheltens, P Vandenberghe, R Gabel, S Meersmans, K Engelborghs, S De Roeck, EE Sleegers, K Frisoni, GB Blin, O Richardson, JC Bordet, R Molinuevo, JL Rami, L Wallin, A Kettunen, P Tsolaki, M Verhey, F Lleo, A Alcolea, D Popp, J Peyratout, G Martinez-Lage, P Tainta, M Johannsen, P Teunissen, CE Freund-Levi, Y Frolich, L Legido-Quigley, C Barkhof, F Blennow, K Zetterberg, H Baker, S Morgan, BP Streffer, J Visser, PJ Bertram, L Lovestone, S Nevado-Holgado, AJ
author_role	author
author2	Westwood, S Baird, AL Winchester, L Dobricic, V Kilpert, F Hong, SJ Franke, A Hye, A Ashton, NJ Morgan, AR Bos, I Vos, SJB Buckley, NJ ten Kate, M Scheltens, P Vandenberghe, R Gabel, S Meersmans, K Engelborghs, S De Roeck, EE Sleegers, K Frisoni, GB Blin, O Richardson, JC Bordet, R Molinuevo, JL Rami, L Wallin, A Kettunen, P Tsolaki, M Verhey, F Lleo, A Alcolea, D Popp, J Peyratout, G Martinez-Lage, P Tainta, M Johannsen, P Teunissen, CE Freund-Levi, Y Frolich, L Legido-Quigley, C Barkhof, F Blennow, K Zetterberg, H Baker, S Morgan, BP Streffer, J Visser, PJ Bertram, L Lovestone, S Nevado-Holgado, AJ
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	Amyloid beta SOMAscan assay Plasma proteomics Replication Causal relationship Tau
topic	Amyloid beta SOMAscan assay Plasma proteomics Replication Causal relationship Tau
description	Introduction: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. Methods: 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid. Results: A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) e4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. Discussion: The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition. (C) 2019 The Authors. Published by Elsevier Inc.
publishDate	2019
dc.date.none.fl_str_mv	2019
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2359
url	https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2359
dc.language.none.fl_str_mv	Inglés
language_invalid_str_mv	Inglés
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.publisher.none.fl_str_mv	WILEY
publisher.none.fl_str_mv	WILEY
dc.source.none.fl_str_mv	ALZHEIMERS & DEMENTIA ISSN: 15525260 ISSNe: 15525279 reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str	Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str	r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection	r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869407797768093696
score	15,812429

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

Similar Items